NHS (National Health Service) cervical screening frequency/range "correct":
This article was originally published in Clinica
Executive Summary
Last year's decision by the UK to reduce the cervical screening call-up interval among women aged 25-49, from five years to three, will substantially reduce the incidence of the disease. So suggest the results of a modelling study by Cancer Research UK and Julietta Patnick, director of the NHS cancer screening programmes. The research published in the British Journal of Cancer (August 2004) shows an 18% fall in cumulative lifetime incidence, compared with pre-2003 policy, and a reduction in the predicted lifetime incidence of invasive cervical cancer, from 0.77% (under pre-2003 policy) to 0.63%, compared with a 1.70% predicted incidence without screening. The research also found that continuing to screen the 20-25 age group would have had minimal impact. A five-year screening interval was retained for women aged 50-64 years.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.